Regen Med. 2018 Jan 23. doi: 10.2217/rme-2017-0089. [Epub ahead of print]

Autologous stem cell therapy for inherited and acquired retinal disease.

Apatoff MBL^1,2, Sengillo JD^1,2,3, White EC², Bakhoum MF², Bassuk AG⁴, Mahajan VB^5,6, Tsang SH^1,2,7,8.

Abstract

The mammalian retina, derived from neural ectoderm, has little regenerative potential. For conditions where irreversible retinal pigment epithelium or photoreceptor cell loss occurs, advanced techniques are required to restore vision. Inherited retinal dystrophies and some acquired conditions, such as age-related macular degeneration, have a similar end result of photoreceptor cell death leading to debilitating vision loss. These diseases stand to benefit from future regenerative medicine as dietary recommendations and current pharmacologic therapy only seek to prevent further disease progression. Cell-based strategies, such as autologously derived induced pluripotent stem cells, have come a long way in overcoming previous technical and ethical concerns. Clinical trials for such techniques are already underway. These trials and the preceding preclinical studies will be discussed in the context of retinal disease.